Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
28 Oct 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
4 May 20
10-K
2019 FY
Annual report
2 Mar 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
5 Aug 19
10-Q
2019 Q1
Quarterly report
30 Apr 19
10-K
2017 FY
Annual report
25 Feb 19
10-Q
2018 Q3
Quarterly report
30 Oct 18
Current reports
8-K
Termination of a Material Definitive Agreement
22 Apr 21
8-K
Entry into a Material Definitive Agreement
15 Mar 21
8-K
Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021
15 Mar 21
8-K
GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results
25 Feb 21
8-K
Departure of Directors or Certain Officers
24 Feb 21
8-K
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020
11 Jan 21
8-K
GenMark Diagnostics Reports Third Quarter 2020 Results
28 Oct 20
8-K
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
8 Oct 20
8-K
Departure of Directors or Certain Officers
23 Sep 20
8-K
Departure of Directors or Certain Officers
11 Sep 20
Registration and prospectus
15-12B
Securities registration termination
3 May 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
Proxies
DEFA14A
Additional proxy soliciting materials
4 May 20
DEFA14A
Additional proxy soliciting materials
15 Apr 20
DEF 14A
Definitive proxy
15 Apr 20
DEFA14A
Additional proxy soliciting materials
17 Apr 19
DEF 14A
Definitive proxy
17 Apr 19
DEFA14A
Additional proxy soliciting materials
13 Apr 18
DEF 14A
Definitive proxy
13 Apr 18
DEF 14A
Definitive proxy
13 Apr 17
DEFA14A
Additional proxy soliciting materials
13 Apr 17
DEFA14A
Additional proxy soliciting materials
15 Apr 16
Other
EFFECT
Notice of effectiveness
28 Apr 21
SD
Conflict minerals disclosure
1 Jun 20
CT ORDER
Confidential treatment order
5 Mar 19
EFFECT
Notice of effectiveness
10 Dec 18
CORRESP
Correspondence with SEC
6 Dec 18
CT ORDER
Confidential treatment order
4 Dec 18
UPLOAD
Letter from SEC
29 Nov 18
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
27 Mar 18
CT ORDER
Confidential treatment order
22 Aug 17
Ownership
SC 13G/A
Consonance Capital Management LP
14 Feb 22
SC 13G/A
WASATCH ADVISORS INC
10 May 21
4
Lisa M. Giles
22 Apr 21
4
Michael Kagnoff
22 Apr 21
4
James Fox
22 Apr 21
4
DARYL FAULKNER
22 Apr 21
4
KEVIN C OBOYLE
22 Apr 21
4
Wade R. Stevenson
22 Apr 21
4
Christine Shaw
22 Apr 21
4
Sarah Hollis Winkler
22 Apr 21